Entera Bio Ltd (ENTX)
NASDAQ:ENTX
Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$1.28
-$0.11(-4.20%)
At close: 4:00 PM EST
$1.28
-$0.11(-4.20%)
Day’s Range― - ―
52-Week Range$0.91 - $3.22
Previous CloseN/A
Volume29.71K
Average Volume (3M)123.78K
Market Cap
$61.04M
Enterprise Value$57.35M
Total Cash (Recent Filing)$4.14M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 07, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding49,225,323
10 Day Avg. Volume240,874
30 Day Avg. Volume123,776
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.82K
Enterprise Value/Ebitda-4.62
Forecast
1Y Price Target
$9.00Price Target Upside603.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$54.58M
Bulls Say, Bears Say
Bulls Say
Regulatory Path Acceleration (EB613)A streamlined Phase 3 via a 505(b)(2) reference to Forteo and a single‑tablet “Next‑Gen” formulation shortens timelines and trial size (≈750 patients, 12‑month hip BMD primary). This structurally improves probability of efficient registration and later commercial adoption versus longer, larger trials.
Partnerships And Pipeline DiversificationA 50/50 collaboration on EB612 spreads development cost and operational risk, while multiple programs (osteoporosis, hypoparathyroidism, GLP candidates) diversify eventual commercial pathways. Long‑term, partnerships can accelerate IND filings and reduce standalone capital requirements.
Low Financial LeverageMinimal debt preserves financial flexibility and reduces near‑term solvency risk, allowing the company to prioritize R&D and negotiate non‑dilutive or staged financings. Over months, low leverage supports strategic options and limits fixed financing costs that could constrain development plans.
Bears Say
Pre-commercial Revenue ProfileWith no meaningful commercial revenue and persistent net losses, the company lacks internally generated funding to progress multiple clinical programs. This structural dependence on external capital creates execution risk over the coming 2–6 months as programs advance toward costlier phase‑3 activities.
High Cash Burn And Limited RunwayOperating and free cash flow losses are large relative to cash on hand. Even after a $10M private placement, management estimates runway into Q1 2027. Sustained negative cash generation means the company will likely need additional financing within the medium term, pressuring resources and strategy.
Equity Dilution And Negative ReturnsDeclining shareholders' equity and materially negative ROE indicate value erosion and prior dilution. As a clinical‑stage biotech, continued reliance on equity raises to fund trials can further dilute holders and complicate incentive alignment, a persistent structural headwind for returns.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $3.22 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $61.04M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on May 08, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.01.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.08.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 49,225,323 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (603.13% Upside)
$9.00 (603.13% Upside)
Insider Transactions
Bought Shares
Worth $45.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.41%
12-Months-Change
Fundamentals
Return on Equity
-87.97%
Trailing 12-Months
Asset Growth
-39.22%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$9.00
▲(603.13% Upside)
Technical Analysis
Ownership Overview
3.47% Insiders
0.04% Mutual Funds
13.15% Other Institutional Investors
83.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---